4.7 Review

Regulation of AID, the B-cell genome mutator

Journal

GENES & DEVELOPMENT
Volume 27, Issue 1, Pages 1-17

Publisher

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.200014.112

Keywords

activation-induced deaminase; DNA repair; transcription; somatic mutations

Funding

  1. NIH [1DP2OD008651-01]
  2. National Institute of Allergy and Infectious Diseases (NIAID) [1R01AI099195-01A1]
  3. Columbia University
  4. Irma Hirschl Foundation
  5. Columbia University, Pathology Educational Fund
  6. NIAID [F31AI098411-01A1]
  7. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI099195, F31AI098411] Funding Source: NIH RePORTER
  8. OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008651] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The mechanisms by which B cells somatically engineer their genomes to generate the vast diversity of antibodies required to challenge the nearly infinite number of antigens that immune systems encounter are of tremendous clinical and academic interest. The DNA cytidine deaminase activation-induced deaminase (AID) catalyzes two of these mechanisms: class switch recombination (CSR) and somatic hypermutation (SHM). Recent discoveries indicate a significant promiscuous targeting of this B-cell mutator enzyme genome-wide. Here we discuss the various regulatory elements that control AID activity and prevent AID from inducing genomic instability and thereby initiating oncogenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available